These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 22746160)

  • 1. A review of olanzapine pamoate.
    Chue P; Chue J
    Expert Opin Pharmacother; 2012 Aug; 13(11):1661-70. PubMed ID: 22746160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olanzapine pamoate for the treatment of schizophrenia--a safety evaluation.
    Samalin L; Garay R; Ameg A; Llorca PM
    Expert Opin Drug Saf; 2016; 15(3):403-11. PubMed ID: 26761429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug safety evaluation of olanzapine pamoate.
    Schöttle D; Kuhnigk O; Naber D
    Expert Opin Drug Saf; 2013 Nov; 12(6):897-903. PubMed ID: 24024627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olanzapine pamoate for the treatment of schizophrenia.
    Naber D
    Expert Opin Pharmacother; 2011 Mar; 12(4):627-33. PubMed ID: 21254860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic.
    Citrome L
    Int J Clin Pract; 2009 Jan; 63(1):140-50. PubMed ID: 18834452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism.
    McDonnell DP; Detke HC; Bergstrom RF; Kothare P; Johnson J; Stickelmeyer M; Sanchez-Felix MV; Sorsaburu S; Mitchell MI
    BMC Psychiatry; 2010 Jun; 10():45. PubMed ID: 20537130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olanzapine: a review of rapid and long-acting parenteral formulations.
    Owen RT
    Drugs Today (Barc); 2010 Mar; 46(3):173-81. PubMed ID: 20467591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olanzapine long-acting injection: a review of its use in the treatment of schizophrenia.
    Frampton JE
    Drugs; 2010 Dec; 70(17):2289-313. PubMed ID: 21080745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-acting injectable antipsychotics and the development of postinjection delirium/sedation syndrome (PDSS).
    Novakovic V; Adel T; Peselow E; Lindenmayer JP
    Clin Neuropharmacol; 2013; 36(2):59-62. PubMed ID: 23503549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia.
    Kane JM; Detke HC; Naber D; Sethuraman G; Lin DY; Bergstrom RF; McDonnell D
    Am J Psychiatry; 2010 Feb; 167(2):181-9. PubMed ID: 20008947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases.
    Detke HC; McDonnell DP; Brunner E; Zhao F; Sorsaburu S; Stefaniak VJ; Corya SA
    BMC Psychiatry; 2010 Jun; 10():43. PubMed ID: 20537128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia.
    Di Lorenzo R; Brogli A
    Neuropsychiatr Dis Treat; 2010 Sep; 6():573-81. PubMed ID: 20856920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection.
    Citrome L
    Patient Prefer Adherence; 2009 Nov; 3():345-55. PubMed ID: 20016798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-Injection Delirium/Sedation Syndrome after Olanzapine Long-Acting Intramuscular Injection - Who is at Risk?
    Łukasik-Głębocka M; Sommerfeld K; Teżyk A; Panieński P; Żaba C; Zielińska-Psuja B
    Basic Clin Pharmacol Toxicol; 2015 Sep; 117(3):213-4. PubMed ID: 25703610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Post-injection delirium/sedation syndrome following injection of olanzapine pamoate: a new syndrome in emergency psychiatry].
    Buts K; Van Hecke J
    Tijdschr Psychiatr; 2014; 56(4):273-6. PubMed ID: 24807388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review.
    Cañas F; Möller HJ
    Expert Opin Drug Saf; 2010 Sep; 9(5):683-97. PubMed ID: 20690885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cost-effectiveness study of olanzapine pamoate: Mirror-image analysis after one year].
    Potaufeu J; Langrée B; Drapier D; Burgot G; Marie N
    Encephale; 2019 Jun; 45(3):232-238. PubMed ID: 30579574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Follow-up study of patients treated with olanzapine pamoate in France in real-life treatment situation.
    Chartier F; Rouillon F; Berggren L; Jamonneau I; Falissard B; Llorca PM
    Encephale; 2017 Aug; 43(4):303-310. PubMed ID: 28709669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Occurrence of post-injection delirium/sedation syndrome after application of olanzapine long-acting injection during one year period.
    Uzun S; Kozumplik O; Ćelić I; Pivac N; Mimica N
    Psychiatr Danub; 2017 Dec; 29(4):497-499. PubMed ID: 29197208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world use patterns of olanzapine long-acting injection in the United States: comparison to the recommended dosing strategy.
    Case MG; Karagianis JL; Schuh KJ; Hoffmann VP
    Curr Med Res Opin; 2013 Nov; 29(11):1533-7. PubMed ID: 23998459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.